Background: Persisting infl ammatory stimuli cause chronic infl ammation recognized as the major factor contributing to the development of a number of diseases. One group of drugs used in the treatment of chronic infl ammation is the group of non-steroidal anti-infl ammatory drugs and, more specifi cally, the selective COX-2 inhibitors (coxibs). However, most of the coxibs were withdrawn from the market in view of their safety profi le. In the present study, 2-[3-Acetyl-5-(4-chlorophenyl)-2-methyl-pyrrol-1-yl]-4-methylsulfanyl-butyric acid (compound 3e), an Npyrrolylcarboxylic acid derivative structurally related to celecoxib, is evaluated for anti-infl ammatory activity after single and multiple (14 days) administration using an animal infl ammation model. Aim: To evaluate the anti-infl ammatory properties of 2-[3-Acetyl-5-(4-chlorophenyl)-2-methyl-pyrrol-1-yl]-4-methylsulfanyl-butyric acid (compound 3e) after single and multiple (14 days) administration using an animal infl ammation model. Materials and methods: Forty Wistar rats were allocated into 5 groups (n=8) treated with saline (controls), diclofenac (25 mg/kg b.w.), compound 3e (10, 20 and 40 mg/kg b.w.) intraperitoneally. The volume of the right hind paw of the animals of all groups is measured prior to treatment and two, three and four hours after administration of carrageenan using a plethysmometer (Ugo Basile, Italy). The percentage of paw edema is calculated using the Trinus formula. Results: In a single administration, compound 3e in doses of 10 and 20 mg/kg b.w. did not inhibit paw edema, while a dose of 40 mg/kg b.w. signifi cantly inhibited carrageenan-induced paw edema at 2 hours in comparison with the control group. After continuous administration, compound 3e in doses of 10, 20 and 40 mg/kg b.w. signifi cantly reduced paw edema at 2, 3, and 4 hours compared to animals treated with saline. Conclusions: Compound 3e shows anti-infl ammatory properties similar to those of diclofenac after continuous administration.
Infl ammation response is an answer to noxious stimuli. 1 Acute infl ammation is a self-limiting process that usually restores tissue homeostasis. Persisting infl ammatory stimuli or deregulation of the resolution phase mechanisms cause chronic infl ammation, which is recognized as a major risk factor for the development of a number of diseases including atherosclerosis, arthritis, and cancer. 2 One group of drugs used in the treatment of chronic infl ammatory diseases are non-steroidal anti-infl ammatory drugs (NSAIDs). NSAIDs are among the most often prescribed drugs. 3 They are the fourth most commonly sold drugs in the global pharmaceutical market after antibiotics, cardiovascular and psychotropic medications. After the discovery of their mechanism of action (inhibition of the cyclooxygenase (COX)) and the identifi cation of two COX isoenzymes, selective COX-2 inhibitors (coxibs) were introduced for the purpose of better gastrointestinal tolerance. However, most of them were withdrawn from the market in view of their safety profi le. [4] [5] [6] This necessitates a search for new drug medications with analgesic and anti-infl ammatory effects.
2-[3-Acetyl-5-(4-chloro-phenyl)-2-methyl-pyrrol-1-yl]-4-methylsulfanyl-butyric acid (compound 3e) is a newly synthesized N-pyrrolylcarboxylic acid derivative. The chemistry, design, synthesis and characterization by spectroscopy and TLC (thin line chromatography) were described by Vladimirova et al. 7 The pyrrolic ring is chosen as a central core due to the involvement of this heterocycle in the pharmacophore system of a large number of classic and contemporary NSAIDs. [8] [9] [10] The structure of the target molecule is oriented to the architecture of the selected prototype for a contemporary antiinfl ammatory agent celecoxib (a selective COX-2 inhibitor), thus expecting manifestation of its characteristic pharmacological activity.
Th e carrageenan model chosen in this study is generally used to assess potential anti-infl ammatory activity of novel substances. The inflammation induced by carrageenan possesses two distinct phases 11 , with prostaglandins playing a major role 12 . This makes the model particularly suitable for registering anti-infl ammatory effect of compounds with suspected COX-blocking mechanism of action.
The aim of the present study was to evaluate the anti-infl ammatory properties of 2-[3-Acetyl-5-(4-chloro-phenyl)-2-methyl-pyrrol-1-yl]-4-methylsulfanyl-butyric acid (compound 3e) after single and multiple (14 days) administration using an animal infl ammation model.
MATERIALS AND METHODS
The experimental setting was approved by the Eth- All substances were dissolved in saline. The drugs were administered intraperitoneally with the doses expressed as milligram salt per kilogram body weight (mg/kg b.w.). The doses used in the experiment were determined according to acute oral toxicity tests. The animals were maintained on a light-dark cycle of 12:12 h in a temperaturecontrolled environment with food and water available ad libitum.
CARRAGEENAN-INDUCED PAW EDEMA.
The volume of the right hind paw of the animals of all groups was measured prior to treatment using a plethysmometer (Ugo Basile, Italy). 0.1 ml of a 1% solution of carrageenan in 0.9% NaCl was injected in the right hind paw of all animals to induce edema. Immediately after injection of carrageenan, the control group was given saline solution intraperitoneally; the positive control group received diclofenac and the animals of groups III, IV and V -compound 3e. The volume of displaced liquid from the right hind paw of the rats was measured using a plethysmometer two, three and four hours after administration of carrageenan. The percentage of paw edema was calculated using the Trinus formula.
Statistical analysis of the results was performed with IBM SPSS 20.0 software. The KolmogorovSmirnov test was used to determine the normality of distribution. Arithmetic mean and standard error of the mean (± SEM) were determined for each indicator. Comparison of the results between groups was performed using the Independent Sample t-test. A p value of < 0.05 was considered statistically signifi cant.
RESULTS
The reference anti-infl ammatory drug diclofenac showed signifi cant reduction in paw edema at all hours after both single and multiple administration.
After a single administration, the compound 3e in doses of 10 and 20 mg/kg b.w. did not inhibit paw edema compared to the animals treated with saline solution. A dose of 40 mg/kg b.w. signifi cantly inhibited the carrageenan-induced paw edema at 2 hours in comparison with the control group. After multiple administration (14 days), compound 3e in doses of 10, 20, and 40 mg/kg b.w. signifi cantly reduced paw edema at 2, 3, and 4 hours compared to animals from the control group.
The specifi c values of paw edema in percentages, as well as the values of t-criterion and p-value are presented in Table 1 . DISCUSSION The results in our study suggest that in experimental conditions 2-[3-Acetyl-5-(4-chloro-phenyl)-2-methyl-pyrrol-1-yl]-4-methylsulfanyl-butyric acid has anti-infl ammatory activity in the carrageenan-induced infl ammation model. This effect is signifi cant after continuous administration of the compound.
The experimental edema induced by carrageenan administration in rats and the acute exudative infl ammation in humans possess huge similarities in vascular and cell reactions. Histamine, serotonin and several pro-infl ammatory cytokines (TNF-α, IL-1β) are involved in the pathogenesis of the carrageenaninduced swelling during the initial vascular phase; afterwards bradykinin mediates increased vascular permeability and prostaglandins participate in the acute infl ammatory reaction during the cellular phase (3-5 hours). 13 Suppression of this last phase is typical of NSAIDs and correlates to a big extent with their therapeutic effi cacy. 13 Compound 3e after multiple administration signifi cantly inhibits paw swelling at 2, 3, and 4 hours, with the most pronounced effect at 4 hours. That would be in line with the expected of this substance cyclooxygenase inhibiting activity. Since the tested substance also inhibits paw edema at the early hours, we can hypothesize that it possesses antagonistic action to all mediators involved in the vascular and cellular phases.
After single administration, compound 3e in a dose 40 mg/kg b.w. inhibits paw swelling at 2 hours and nearly reaches signifi cance at 4 hours. We could speculate that higher doses are necessary for blocking COX effectively. This could hint at a competitive inhibition mechanism and at possible linear kinetics and graded dose-response relationship. After continuous administration the registered anti-infl ammatory effect is signifi cant and persistent even at dose of 10 mg/kg b.w., which could indicate that accumulation of the compound is necessary for stable binding with COX at low doses. Since the Lessigiarska et al. found that the compounds significantly inhibited paw edema, showing anti-infl ammatory effect greater even than that of indomethacin which was used as a reference drug. [14] [15] [16] This confi rms the signifi cance of the pyrrolic heterocycle for the anti-infl ammatory effect shown by compound 3e.
Further in vitro studies of COX-1/COX-2 activity and selectivity of the compound are necessary to establish the specifi c mechanisms of anti-infl ammatory action of compound 3e.
CONCLUSIONS
Compound 3e -(2-[3-Acetyl-5-(4-chloro-phenyl)-2-methyl-pyrrol-1-yl]-4-methylsulfanyl-butyric acid) shows signifi cant anti-infl ammatory activity, inhibiting both vascular and cellular phases of infl ammation after multiple (14 days) administration in rats. The anti-infl ammatory effect is similar to the one induced by diclofenac, which suggests suitability of the compound as a potential novel anti-infl ammatory drug.
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